These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28035034)

  • 1. Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS).
    Sullinger S; Bryand K; Kerrigan S
    J Anal Toxicol; 2017 Apr; 41(3):224-229. PubMed ID: 28035034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of suvorexant in blood using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry.
    Skillman B; Kerrigan S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():87-95. PubMed ID: 29859493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of suvorexant in urine using gas chromatography/mass spectrometry.
    Carson M; Kerrigan S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():289-294. PubMed ID: 27825624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Suvorexant in Blood Using LC-MS-MS: Important Considerations for Matrix Effects and Quantitative Interferences in Targeted Assays.
    Skillman B; Kerrigan S
    J Anal Toxicol; 2020 Apr; 44(3):245-255. PubMed ID: 31788700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens.
    Skillman B; Kerrigan S
    Forensic Sci Int; 2020 Jul; 312():110307. PubMed ID: 32473525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UPLC-MS/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets.
    Iqbal M; Ezzeldin E; Khalil NY; Alam P; Al-Rashood KA
    J Pharm Biomed Anal; 2019 Feb; 164():1-8. PubMed ID: 30339947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple and Highly Sensitive UPLC-ESI-MS/MS Assay for Rapid Determination of Suvorexant in Plasma.
    Iqbal M; Ezzeldin E; Khalil NY; Al-Rashood ST; Al-Rashood KA
    J Anal Toxicol; 2017 Mar; 41(2):114-120. PubMed ID: 28376227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-mediated ion suppression and mitigation of interferences using liquid chromatography-quadrupole/time of flight mass spectrometry (LC-Q/TOF-MS) and liquid chromatography tandem mass spectrometry (LC-MS/MS).
    Skillman B; Kerrigan S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122265. PubMed ID: 32721861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection.
    Breidinger SA; Simpson RC; Mangin E; Woolf EJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():254-9. PubMed ID: 26343269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 11. Simultaneous Screening and Quantification of Basic, Neutral and Acidic Drugs in Blood Using UPLC-QTOF-MS.
    Bidny S; Gago K; Chung P; Albertyn D; Pasin D
    J Anal Toxicol; 2017 Apr; 41(3):181-195. PubMed ID: 27881618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples.
    Ishikawa H; Furugen A; Nishimura A; Umazume T; Ishikawa S; Aoyagi R; Narumi K; Okamoto K; Takekuma Y; Sugawara M; Kobayashi M
    J Pharm Biomed Anal; 2024 Dec; 251():116432. PubMed ID: 39180895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases.
    Waters B; Hara K; Ikematsu N; Takayama M; Matsusue A; Kashiwagi M; Kubo SI
    J Anal Toxicol; 2018 May; 42(4):276-283. PubMed ID: 29300899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General unknown screening in hair by liquid chromatography-hybrid quadrupole time-of-flight mass spectrometry (LC-QTOF-MS).
    Broecker S; Herre S; Pragst F
    Forensic Sci Int; 2012 May; 218(1-3):68-81. PubMed ID: 22036310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and quantification of synthetic cathinones in blood and urine using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry.
    Glicksberg L; Bryand K; Kerrigan S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1035():91-103. PubMed ID: 27697731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of new designer drugs in post-mortem blood using high-resolution mass spectrometry.
    Pasin D; Bidny S; Fu S
    J Anal Toxicol; 2015 Apr; 39(3):163-71. PubMed ID: 25552261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.